Pieris Pharmaceuticals stock (US72016P1057): Symbol change to PVLA signals transformation

Pieris Pharmaceuticals (PIRS) underwent a CUSIP and symbol change to PVLA, as reported by Robinhood's corporate actions tracker. The biotech firm, listed on Nasdaq, continues developing Anticalin-based therapies for oncology and respiratory diseases amid ongoing pipeline progress.

Pieris Pharmaceuticals, a clinical-stage biotech company, recently executed a CUSIP change and symbol change from PIRS to PVLA, according to Robinhood corporate actions tracker as of May 2026. This corporate action reflects structural updates common in the biotech sector. The company maintains its focus on the proprietary Anticalin platform for targeted therapeutics.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pieris Pharmaceuticals
• Sector/industry: Biotechnologie
• Headquarters/country: Boston/USA
• Core markets: Onkologie, Atemwegserkrankungen
• Key revenue drivers: Partnerschaften mit Pharmafirmen
• Home exchange/listing venue: Nasdaq (PIRS/PVLA)
• Trading currency: USD

Pieris Pharmaceuticals: core business model

Pieris Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary Anticalin technology platform to develop differentiated drugs. Based on engineered lipocalin proteins, Anticalins offer high specificity and better tissue penetration compared to traditional antibodies, as described in Ad-hoc-news.de as of 14.05.2026. The platform targets validated pathological pathways in oncology and respiratory diseases.

The company's pipeline includes an inhaled Anticalin antagonist of IL-4Ra for asthma and immuno-oncology bispecifics targeting HER2/4-1BB and PD-L1/4-1BB. Pieris generates revenue through partnerships, milestone payments, and royalties. Headquartered in Boston, Massachusetts, it has been Nasdaq-listed since 2014, providing US investors access to innovative biopharma plays.

Main revenue and product drivers for Pieris Pharmaceuticals

Pieris Pharmaceuticals derives key revenue from collaborations with major pharma firms, licensing its Anticalin technology for drug development. Core markets include oncology and respiratory conditions, with pipeline candidates advancing in clinical stages. The firm's model emphasizes smaller, modular proteins for enhanced efficacy, according to company overviews on Investing.com as of May 2026.

US investors benefit from Pieris' Nasdaq listing and exposure to the booming biotech sector, which plays a critical role in advancing therapies amid rising demand for precision medicines in the American healthcare market.

Conclusion

Pieris Pharmaceuticals continues to advance its Anticalin platform amid a recent symbol change to PVLA, highlighting ongoing corporate evolution. The biotech's focus on oncology and respiratory therapies positions it within high-growth areas relevant to US investors via Nasdaq trading. Market dynamics in biopharma remain volatile, with partnership-driven revenues supporting pipeline development.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.